

Genotype 1b

TABLE 98: SVR GENOTYPE 1B TREATMENT-NAIVE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	1.61 (0.45 to 2.21)	32.42 (-30.84 to 52.91)
SOF12 + LDV12		1.89 (1.58 to 2.34)	46.27 (35.84 to 56.27)
SOF8 + LDV8 + RBV8		1.80 (1.24 to 2.27)	42.38 (12.79 to 54.54)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + LDV12 + RBV12		1.86 (1.55 to 2.30)	44.72 (34.24 to 54.62)
SOF24 + LDV24 + RBV24		1.88 (1.57 to 2.33)	45.84 (35.66 to 55.77)
T12 PR24-48 RGT q8		1.55 (1.26 to 1.88)	28.65 (13.95 to 39.73)
T12 PR24-48 RGT q12		1.59 (1.20 to 1.97)	31.18 (10.76 to 43.56)
T12 PR48 q8		0.91 (0.14 to 1.96)	-4.66 (-49.63 to 43.21)
SIM12 PR24-48 RGT		1.63 (1.39 to 1.96)	32.49 (23.21 to 41.49)
SOF24 + RBV (low dose) 24		1.55 (0.34 to 2.19)	29.11 (-36.80 to 52.21)
PAR/RIT12 + OMB12 + DAS12		1.86 (1.43 to 2.33)	45.17 (24.22 to 56.26)
DCV24 + ASU24		1.76 (1.48 to 2.13)	39.23 (29.63 to 48.07)
SOF12 + PR12		1.56 (0.56 to 2.09)	29.69 (-22.86 to 48.94)
B44 PR48		1.40 (0.66 to 2.03)	21.14 (-18.64 to 46.21)
B24 PR28-48 RGT		1.44 (1.14 to 1.77)	23.27 (7.11 to 35.64)
SOF12 + LDV12	SOF24 + RBV24	1.16 (0.99 to 3.89)	13.39 (-1.27 to 72.97)
SOF8 + LDV8 + RBV8		1.11 (0.74 to 3.75)	9.59 (-23.98 to 70.02)
SOF12 + LDV12 + RBV12		1.14 (0.97 to 3.85)	11.75 (-3.25 to 71.80)
SOF24 + LDV24 + RBV24		1.15 (0.99 to 3.88)	12.96 (-1.25 to 72.61)
T12 PR24-48 RGT q8		0.96 (0.70 to 3.28)	-3.52 (-28.09 to 58.09)
T12 PR24-48 RGT q12		0.99 (0.69 to 3.37)	-1.09 (-29.08 to 60.37)
T12 PR48 q8		0.61 (0.09 to 2.15)	-31.57 (-83.16 to 33.80)
SIM12 PR24-48 RGT		1.00 (0.80 to 3.42)	0.11 (-19.06 to 61.60)
SOF24 + RBV (low dose) 24		0.97 (0.47 to 1.36)	-2.40 (-32.62 to 17.24)
PAR/RIT12 + OMB12 + DAS12		1.14 (0.90 to 3.79)	12.02 (-8.80 to 70.94)
DCV24 + ASU24		1.08 (0.89 to 3.67)	6.41 (-10.31 to 67.36)
SOF12 + PR12		0.99 (0.37 to 3.00)	-0.89 (-56.03 to 53.99)
B44 PR48		0.89 (0.41 to 2.98)	-9.32 (-53.27 to 51.54)
B24 PR28-48 RGT		0.90 (0.63 to 3.14)	-8.87 (-34.44 to 54.25)
SOF8 + LDV8 + RBV8	SOF12 + LDV12	0.98 (0.66 to 1.02)	-2.10 (-33.13 to 1.82)
SOF12 + LDV12 + RBV12		0.99 (0.93 to 1.02)	-1.24 (-7.05 to 2.22)
SOF24 + LDV24 + RBV24		1.00 (0.96 to 1.04)	-0.43 (-3.97 to 3.60)
T12 PR24-48 RGT q8		0.83 (0.65 to 0.93)	-17.05 (-34.24 to -7.15)
T12 PR24-48 RGT q12		0.85 (0.63 to 0.96)	-14.41 (-36.64 to -3.97)
T12 PR48 q8		0.48 (0.08 to 0.92)	-50.85 (-90.61 to -7.88)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 PR24-48 RGT		0.86 (0.76 to 0.93)	-13.37 (-23.28 to -6.45)
SOF24 + RBV (low dose) 24		0.83 (0.18 to 1.01)	-16.99 (-80.32 to 0.96)
PAR/RIT12 + OMB12 + DAS12		1.00 (0.78 to 1.04)	-0.27 (-21.18 to 3.98)
DCV24 + ASU24		0.93 (0.85 to 0.98)	-6.71 (-14.51 to -1.51)
SOF12 + PR12		0.84 (0.30 to 0.99)	-15.68 (-67.64 to -1.46)
B44 PR48		0.75 (0.35 to 0.96)	-24.79 (-63.70 to -3.60)
B24 PR28-48 RGT		0.77 (0.58 to 0.90)	-22.61 (-41.21 to -10.17)
SOF12 + LDV12 + RBV12	SOF8 + LDV8 + RBV8	1.01 (0.94 to 1.50)	0.86 (-5.44 to 31.92)
SOF24 + LDV24 + RBV24		1.02 (0.97 to 1.53)	1.74 (-3.13 to 33.70)
T12 PR24-48 RGT q8		0.86 (0.68 to 1.26)	-13.31 (-31.35 to 16.90)
T12 PR24-48 RGT q12		0.89 (0.65 to 1.30)	-10.67 (-33.66 to 20.06)
T12 PR48 q8		0.51 (0.08 to 1.06)	-45.81 (-89.02 to 4.32)
SIM12 PR24-48 RGT		0.90 (0.78 to 1.32)	-10.12 (-21.21 to 20.54)
SOF24 + RBV (low dose) 24		0.86 (0.19 to 1.34)	-13.20 (-77.61 to 22.68)
PAR/RIT12 + OMB12 + DAS12		1.02 (0.81 to 1.51)	1.73 (-18.32 to 32.56)
DCV24 + ASU24		0.96 (0.87 to 1.43)	-3.96 (-13.03 to 27.37)
SOF12 + PR12		0.88 (0.33 to 1.26)	-11.63 (-61.29 to 17.62)
B44 PR48		0.79 (0.37 to 1.20)	-20.28 (-60.49 to 14.47)
B24 PR28-48 RGT		0.80 (0.60 to 1.19)	-18.73 (-38.20 to 12.51)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.01 (0.97 to 1.08)	0.85 (-3.13 to 7.29)
T12 PR24-48 RGT q8		0.84 (0.67 to 0.95)	-15.62 (-32.35 to -4.92)
T12 PR24-48 RGT q12		0.87 (0.64 to 0.98)	-13.01 (-35.14 to -1.76)
T12 PR48 q8		0.49 (0.08 to 0.94)	-49.32 (-89.22 to -5.24)
SIM12 PR24-48 RGT		0.88 (0.77 to 0.96)	-11.92 (-21.89 to -4.01)
SOF24 + RBV (low dose) 24		0.84 (0.19 to 1.03)	-15.57 (-78.13 to 3.08)
PAR/RIT12 + OMB12 + DAS12		1.01 (0.80 to 1.08)	0.83 (-19.46 to 7.42)
DCV24 + ASU24		0.94 (0.86 to 1.02)	-5.36 (-13.20 to 1.62)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + PR12		0.85 (0.30 to 1.01)	-14.22 (-66.65 to 0.98)
B44 PR48		0.76 (0.36 to 0.98)	-23.34 (-62.17 to -1.43)
B24 PR28-48 RGT		0.78 (0.59 to 0.92)	-21.07 (-39.83 to -8.09)
T12 PR24-48 RGT q8	SOF24 + LDV24 + RBV24	0.83 (0.66 to 0.93)	-16.63 (-33.67 to -6.84)
T12 PR24-48 RGT q12		0.86 (0.63 to 0.96)	-13.97 (-36.40 to -3.63)
T12 PR48 q8		0.49 (0.08 to 0.92)	-50.38 (-90.03 to -7.37)
SIM12 PR24-48 RGT		0.87 (0.77 to 0.93)	-12.91 (-22.41 to -6.59)
SOF24 + RBV (low dose) 24		0.83 (0.18 to 1.01)	-16.66 (-80.03 to 0.92)
PAR/RIT12 + OMB12 + DAS12		1.00 (0.80 to 1.03)	0.14 (-19.81 to 3.30)
DCV24 + ASU24		0.94 (0.86 to 0.98)	-6.27 (-13.95 to -1.56)
SOF12 + PR12		0.84 (0.30 to 1.00)	-15.25 (-68.65 to 0.16)
B44 PR48		0.75 (0.35 to 0.97)	-24.45 (-63.23 to -3.27)
B24 PR28-48 RGT		0.77 (0.58 to 0.90)	-22.11 (-40.91 to -9.73)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	1.03 (0.85 to 1.18)	2.44 (-11.01 to 12.67)
T12 PR48 q8		0.59 (0.10 to 1.20)	-32.85 (-77.17 to 14.68)
SIM12 PR24-48 RGT		1.05 (0.90 to 1.31)	3.69 (-8.43 to 20.03)
SOF24 + RBV (low dose) 24		1.00 (0.22 to 1.40)	0.15 (-64.79 to 27.16)
PAR/RIT12 + OMB12 + DAS12		1.20 (0.94 to 1.52)	16.02 (-4.85 to 33.61)
DCV24 + ASU24		1.13 (0.99 to 1.41)	10.24 (-0.76 to 26.40)
SOF12 + PR12		1.01 (0.37 to 1.35)	1.07 (-51.15 to 24.14)
B44 PR48		0.91 (0.43 to 1.30)	-7.46 (-47.44 to 20.42)
B24 PR28-48 RGT		0.93 (0.71 to 1.19)	-5.37 (-24.20 to 12.72)
T12 PR48 q8	T12 PR24-48 RGT q12	0.58 (0.09 to 1.21)	-34.90 (-79.73 to 14.76)
SIM12 PR24-48 RGT		1.01 (0.87 to 1.37)	1.10 (-11.83 to 23.02)
SOF24 + RBV (low dose) 24		0.97 (0.22 to 1.43)	-2.38 (-66.96 to 27.86)
PAR/RIT12 + OMB12 + DAS12		1.16 (0.91 to 1.58)	13.28 (-7.70 to 36.01)
DCV24 + ASU24		1.09 (0.96 to 1.47)	7.65 (-4.05 to 29.18)
SOF12 + PR12		0.99 (0.36 to 1.38)	-1.19 (-53.77 to 25.00)
B44 PR48		0.88 (0.41 to 1.32)	-9.73 (-50.74 to 21.09)
B24 PR28-48 RGT		0.91 (0.68 to 1.23)	-7.70 (-27.68 to 14.97)
SIM12 PR24-48 RGT	T12 PR48 q8	1.79 (0.90 to 10.83)	37.30 (-8.69 to 79.20)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV (low dose) 24		1.54 (0.34 to 10.10)	27.52 (-45.07 to 82.96)
PAR/RIT12 + OMB12 + DAS12		2.03 (1.04 to 12.20)	48.91 (3.76 to 90.03)
DCV24 + ASU24		1.93 (0.99 to 11.57)	43.90 (-0.82 to 85.06)
SOF12 + PR12		1.63 (0.51 to 10.29)	30.35 (-34.70 to 81.80)
B44 PR48		1.50 (0.53 to 9.62)	24.04 (-36.62 to 74.32)
B24 PR28-48 RGT		1.58 (0.75 to 9.94)	27.55 (-21.79 to 73.14)
SOF24 + RBV (low dose) 24	SIM12 PR24-48 RGT	0.96 (0.21 to 1.24)	-3.69 (-67.92 to 18.29)
PAR/RIT12 + OMB12 + DAS12		1.15 (0.91 to 1.30)	12.44 (-7.68 to 22.67)
DCV24 + ASU24		1.08 (1.00 to 1.19)	6.49 (0.05 to 14.54)
SOF12 + PR12		0.97 (0.34 to 1.20)	-2.37 (-55.54 to 15.96)
B44 PR48		0.87 (0.41 to 1.16)	-11.38 (-50.86 to 12.40)
B24 PR28-48 RGT		0.89 (0.68 to 1.06)	-9.01 (-27.27 to 4.57)
PAR/RIT12 + OMB12 + DAS12	SOF24 + RBV (low dose) 24	1.19 (0.92 to 5.32)	15.82 (-7.69 to 78.79)
DCV24 + ASU24		1.12 (0.90 to 5.11)	10.03 (-9.82 to 74.10)
SOF12 + PR12		1.03 (0.38 to 3.92)	2.09 (-54.57 to 61.66)
B44 PR48		0.93 (0.42 to 4.32)	-5.84 (-51.26 to 60.84)
B24 PR28-48 RGT		0.93 (0.64 to 4.18)	-5.41 (-33.74 to 59.61)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12	0.94 (0.85 to 1.18)	-6.05 (-14.35 to 14.19)
SOF12 + PR12		0.85 (0.31 to 1.06)	-14.25 (-67.21 to 5.44)
B44 PR48		0.76 (0.36 to 1.04)	-23.39 (-62.48 to 3.58)
B24 PR28-48 RGT		0.78 (0.58 to 1.02)	-21.36 (-40.77 to 1.41)
SOF12 + PR12	DCV24 + ASU24	0.90 (0.32 to 1.09)	-8.79 (-62.11 to 8.07)
B44 PR48		0.80 (0.38 to 1.05)	-17.95 (-57.21 to 4.62)
B24 PR28-48 RGT		0.83 (0.63 to 0.97)	-15.61 (-33.65 to -3.02)
B44 PR48	SOF12 + PR12	0.90 (0.41 to 2.56)	-7.97 (-52.90 to 50.18)
B24 PR28-48 RGT		0.93 (0.67 to 2.59)	-6.22 (-31.00 to 47.14)
B24 PR28-48 RGT	B44 PR48	1.03 (0.69 to 2.20)	2.19 (-27.37 to 42.50)
Random effect model	Residual deviance	39.64 vs. 42 data points	
	Deviance information criteria	209.409	
Fixed effect model	Residual deviance	39.56 vs. 42 data points	
	Deviance information criteria	208.133	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.